| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fe2d8a10ec14cd3998ef9c0637e811b1 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2318-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1136
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-249
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-555
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 |
| filingDate |
2020-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ab30439eae6e51b9d9643d051cd07128
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3213da34346b117089c54301e8c4c726
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c8ad4b2590c5d15c31f4dcf497a9ed7b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c58bf222816f9d71119169f8aa22cef
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_34ccae2668b0b686d13ba6f075ff8b60 |
| publicationDate |
2021-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2021050744-A2 |
| titleOfInvention |
Treatment methods for eye disorders |
| abstract |
A method of inhibiting neutrophil activation in retinal pigment epithelial (RPE) cells comprising administering an inhibitor of interferon (IFN) λ to a subject in need thereof, as well as a method of restoring lysosomal function of RPE cells comprising administering a polypeptide comprising βA1-crystallin or a nucleic acid encoding the polypeptide to a subject in need thereof, are provided. A method of rejuvenating Vacuolar-type H+-ATPase (V-ATPase) activity in RPE cells by modulating assembly and disassembly of the V-ATPase in a subject in need thereof also is provided. Additionally, a method of treating diabetic retinopathy in a subject comprising administering a polypeptide comprising βA1-crystallin or a nucleic acid encoding the polypeptide to the subject is provided. |
| priorityDate |
2019-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |